Company news

Alvotech news in 2022

Alvotech's news releases, calls and decks from 2022, newest first.

View company

Alvotech Completes $59.7 Million Private Placement

December 15, 2022

Alvotech Shares Start Trading on Nasdaq Iceland Main Market

December 7, 2022

Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe

December 6, 2022

Alvotech Announces Changes to its Leadership Team

November 30, 2022

Alvotech Submits its Application for Admission of the Company’s Shares to Trading on Nasdaq Iceland Main Market

November 29, 2022

Alvotech Secures Financing Facilities of Approximately $136 Million

November 15, 2022

Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update

November 14, 2022

Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira®

November 13, 2022

Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference

November 9, 2022

Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8: 00 am ET on November 16, 2022

October 26, 2022

Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care

October 18, 2022

Alvotech’s Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan

October 16, 2022

Alvotech Appoints Sarah Tanksley as Chief Quality Officer

October 10, 2022

Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra®

September 21, 2022

Alvotech Reports Update on Initial AVT02 Biologics License Application

September 4, 2022

Alvotech Reports First Half 2022 Financial Results and Business Update

August 30, 2022

Alvotech Announces Corporate Sustainability Participation and Discloses ESG Data covering 2020 and 2021

August 28, 2022

Alvotech Initiates Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

August 24, 2022

Alvotech to Report First Six Months and Second Quarter 2022 Financial Results on August 31, 2022 and Host Business Update Conference Call at 8: 00 am ET on September 1, 2022

August 14, 2022

Alvotech’s Board of Directors Approves Plan to Prepare for Listing on Nasdaq Main Market in Iceland

August 11, 2022

Alvotech Initiates a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

July 19, 2022

Alvotech Expands its Board of Directors as part of Transition from Private to Publicly Traded Company

July 13, 2022

Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea®

July 6, 2022

Calls in 2022

Decks in 2022